Retatrutide lowers HbA1c by up to 1.94% in its first type 2 diabetes phase 3 trial
The Lancet published TRANSCEND-T2D-1, the first phase 3 trial of retatrutide (a weekly GIP, GLP-1 and glucagon receptor agonist) in type 2 diabetes, as the results were presented at the ADA Scientific Sessions. In 537 adults whose diabetes was not controlled by diet and exercise, HbA1c fell by 1.69% to 1.94% across three doses after 40 weeks, versus 0.81% with placebo, and body weight fell by up to 15.3% versus 2.6%. Side effects were mainly gastrointestinal, and retatrutide remains investigational and unapproved.
Sources
- 01Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial(opens the source in a new tab)
- 02PubMed record 42250575(opens the source in a new tab)
- 03Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea(opens the source in a new tab)